- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03087032
Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD) (LiraGooD)
August 4, 2020 updated by: The First Affiliated Hospital of Xiamen University
Efficacy and Safety of Liraglutide-bolus (Liraglutide Plus Prandial Insulin) Versus Glargine-bolus Therapy in Overweight / Obese Patients With Uncontrolled Type 2 Diabetes (LiraGooD)--A Multicenter Randomized Controlled Study
The present 24-week, prospective, open-label, randomized, multicenter, parallel group trial is carried to investigate and evaluate the efficacy and safety of Liraglutide in combination with prandial insulin therapy vs insulin glargine in combination with prandial insulin therapy in overweight / obese patients with uncontrolled type 2 diabetes.
Study Overview
Status
Unknown
Intervention / Treatment
Detailed Description
An increasing number of patients with type 2 diabetes are treated with insulin.
Patients with diabetes receiving intensive insulin therapy with various combinations of basal and prandial insulin can be caught in a vicious but common cycle, whereby insulin requirements increase over time, and this in turn contributes to weight gain and hypoglycemia and further increases in insulin dosing.
At this stage, clinicians observe a practical limit to the efficacy of insulin titration alone on glucose-lowering and often add or continue metformin to reduce insulin resistance.
Injectable glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as liraglutide, are a relatively new addition to our treatment armamentarium.
These drugs improve glucose control and insulin sensitivity and contribute to weight loss.
Treatment with basal insulin plus GLP-1RAs is well-established in diabetes guidelines and may be as effective as adding prandial insulin therapy.
When GLP-1 RAs are started, a preemptive reduction in insulin dosage by 25% to 30% in patients with HbA1c < 9% may reduce the risk for hypoglycemia.
In overweight/obese patients with uncontrolled type 2 diabetes treated with more than three oral antidiabetic drugs (OADs) or high doses of premix insulin, Is basal-prandial insulin therapy the option treatment algorithm?
Such an intensification strategy carries risk of increased hypoglycaemia and weight gain, both of which are associated with worse long-term outcomes.
There have no randomized, controlled trials to evaluate the efficacy and safety of GLP-1 RAs vs insulin glargine added to prandial insulin in overweight/obese patients with uncontrolled type 2 diabetes.
So, the current 24-week, prospective, open-label, randomized, multicenter, parallel group trial will be preformed to assess whether Liraglutide plus prandial insulin therapy was noninferior to glargine plus prandial insulin therapy in overweight/obese patients with uncontrolled type 2 diabetes。
Study Type
Interventional
Enrollment (Anticipated)
140
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Changqin Liu, MD
- Phone Number: +86-133-7698-6106
- Email: liuchangqin@xmu.edu.cn
Study Contact Backup
- Name: Xin Zheng, MD
- Phone Number: +86-187-0592-9102
- Email: 88126386@qq.com
Study Locations
-
-
Fujian
-
Xiamen, Fujian, China, 361003
- Recruiting
- The first afilliated hospital of Xiamen university
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age: 18 - 75 years old.
- BMI must be greater than 24 and less than 45 kg/m2
- Patients with type 2 diabetes who met the World Health Organization (who) diagnostic criteria (1999).
- Newly diagnosed type 2 diabetic patients with HbA1c ≥ 9.0%;or patients with uncontrolled type 2 diabetes (HbA1c ≥ 7.5% ) who have received at least two types of oral hypoglycemic drugs (the dose of each drug needs to reach the second largest dose or more), or only insulin (excluding basal-bolus insulin therapy), or insulin with oral hypoglycemic drugs.
- Signed informed consent.
Exclusion Criteria:
- History of pancreatic disease,
- History of medullary thyroid carcinoma
- Lipase level > 3 times above normal,
- Creatinine clearance ≤ 30 mL/min/1.73m2,
- Evidence in the last 6 months of significant heart disease or stroke, including myocardial infarction, unstable angina, coronary bypass and/or percutaneous transluminal coronary angioplasty, congestive heart failure (New York Heart Association Functional Classification III-IV), or severe ischemic heart disease.
- Preparation for pregnancy or having been in pregnancy
- Researchers believe that there are any factors that affect assessing subjects' participation in trial.
- Patients unable to cooperate in clinical trials
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Liraglutide-bolus
'Liraglutide-bolus'(Liraglutide once-daily plus thrice-daily prandial insulin lispro).
Patients will receive adding Liraglutide to prandial insulin Lispro.
The starting liraglutide dose was 0.6mg/day, then 1.2mg/day after 1 week and 1.8mg/day after a further week.
The dose was maintained until study completion.
Dose of insulin Lispro will be instructed on a titration schedule, adjusted every 3 days.
|
Patients will receive adding Liraglutide to prandial insulin Lispro.
The starting liraglutide dose was 0.6mg/day, then 1.2mg/day after 1 week and 1.8mg/day after a further week.
The dose was maintained until study completion.
Dose of insulin Lispro will be instructed on a titration schedule, adjusted every 3 days.
Other Names:
|
ACTIVE_COMPARATOR: Basal-bolus
'Basal-bolus' (insulin glargine once-daily plus thrice-daily prandial insulin lispro).
Patients will receive adding insulin Glargine to prandial insulin Lispro.Dose of insulin will be instructed on a titration schedule, adjusted every 3 days.
Patients subcutaneously self-injected once-daily at approximately the same time each day.
|
Individuals randomized to adding insulin Glargine to prandial insulin Lispro will be instructed on a titration schedule, adjusted every 3 days.
Patients subcutaneously self-injected once-daily at approximately the same time each day.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in HbA1c level after 24 weeks,with a noninferiority margin of 0.3%
Time Frame: 24 weeks
|
the net change in glycated hemoglobin level is less than 0.3%
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
changes from baseline in FPG(mmol/L)
Time Frame: 24 weeks
|
changes from baseline in FPG(mmol/L)
|
24 weeks
|
changes in body weight ( kilograms)
Time Frame: 24 weeks
|
changes in body weight( kilograms)
|
24 weeks
|
changes in prandial insulin dosage (per kilogram)
Time Frame: 24 weeks
|
changes in prandial insulin dosage (per kilogram)
|
24 weeks
|
changes in visceral as assessed by dual x-ray absorptiometry (DXA)
Time Frame: 24 weeks
|
changes in visceral as assessed by dual x-ray absorptiometry (DXA)
|
24 weeks
|
number of participants with abnormal laboratory values and/or adverse events that are related to treatment
Time Frame: 24 weeks
|
number of participants with abnormal laboratory values and/or adverse events
|
24 weeks
|
changes in abdominal circumference
Time Frame: 24 weeks
|
changes in abdominal circumference
|
24 weeks
|
changes in waist circumference
Time Frame: 24 weeks
|
changes in waist circumference
|
24 weeks
|
changes in serum c-peptide level
Time Frame: 24 weeks
|
changes in serum c-peptide level
|
24 weeks
|
changes in systolic pressure
Time Frame: 24 weeks
|
changes in systolic pressure
|
24 weeks
|
changes in diastolic pressure
Time Frame: 24 weeks
|
changes in diastolic pressure
|
24 weeks
|
changes in serum lipid profile
Time Frame: 24 weeks
|
changes in serum lipid profile
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Xuejun Li, MD, The first afilliated hospital of Xiamen university
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 10, 2019
Primary Completion (ANTICIPATED)
December 1, 2021
Study Completion (ANTICIPATED)
December 31, 2021
Study Registration Dates
First Submitted
March 8, 2017
First Submitted That Met QC Criteria
March 16, 2017
First Posted (ACTUAL)
March 22, 2017
Study Record Updates
Last Update Posted (ACTUAL)
August 6, 2020
Last Update Submitted That Met QC Criteria
August 4, 2020
Last Verified
August 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Body Weight
- Hyperglycemia
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Overweight
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Incretins
- Liraglutide
- Insulin Glargine
Other Study ID Numbers
- KYH2017-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overweight and Obesity
-
University Hospital, LilleNational Research Agency, France; European Union; University of Lille Nord de... and other collaboratorsNot yet recruitingOverweight and Obesity | Overweight, Childhood | Overweight, Infant
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Institut Investigacio Sanitaria Pere VirgiliCompletedObesity, Childhood | Overweight and Obesity | Overweight, ChildhoodSpain
-
Memorial Sloan Kettering Cancer CenterRecruitingObesity | Overweight | Overweight and Obesity | Obese | Overweight or ObesityUnited States
-
Holbaek SygehusUniversity of Copenhagen; University of Florida; University of Minnesota; Hebrew... and other collaboratorsRecruitingChildhood Overweight and ObesityDenmark
-
Universidade do Extremo Sul Catarinense - Unidade...RecruitingObesity | Overweight and Obesity | Obesity; Endocrine | Overweight, Obesity and Other HyperalimentationBrazil
-
Mexican National Institute of Public HealthUNICEFCompleted
-
Universidade do PortoFundação para a Ciência e a Tecnologia; Administração Regional de Saúde do... and other collaboratorsCompletedOverweight and ObesityPortugal
-
University of British ColumbiaTerminatedOverweight and ObesityCanada
-
National Taiwan University HospitalCompleted
Clinical Trials on Liraglutide
-
Woman'sNovo Nordisk A/SCompletedPolycystic Ovary Syndrome | Pre Diabetes | Obesity AndroidUnited States
-
Novo Nordisk A/SCompleted
-
The Affiliated Hospital of Qingdao UniversityCompletedTherapeutic EquivalencyChina
-
Sunshine Lake Pharma Co., Ltd.Completed
-
Merck Sharp & Dohme LLCCompleted
-
Henrik GudbergsenCompletedObesity | OsteoarthritisDenmark
-
Parker Research InstituteCompletedOsteoarthritis, KneeDenmark
-
Henrik GudbergsenNovo Nordisk A/S; Cambridge Weight Plan LimitedCompleted
-
Henrik GudbergsenCompletedUltrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance (US-LOSEIT-II)Obesity | OsteoarthritisDenmark
-
Henrik GudbergsenCompletedObesity | OsteoarthritisDenmark